Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03995108 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
A Phase 3 study of WHIM Syndrome, sponsored by X4 Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 31
- Enrollment target
- 20
- Study locations
NCT03995108 is a Phase 3 study of WHIM Syndrome that is active but no longer recruiting, run by X4 Pharmaceuticals. The registered enrollment target is 31 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT03995108, a Phase 3 study of WHIM Syndrome, is active but no longer recruiting, sponsored by X4 Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 31 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study has a double-blind, Randomized Placebo-Controlled Period and an Open-Label Period. The primary objective of the Randomized Placebo-Controlled Period is to demonstrate the efficacy of mavorixafor in participants with WHIM syndrome as assessed by increasing levels of circulating neutrophils compared with placebo, and relative to a clinically meaningful threshold. The primary objective of the Open-Label Period is to evaluate the safety and tolerability of mavorixafor in participants with WHIM syndrome. Participants are allowed to continue treatment in the Open-Label Period, if regionally applicable, until mavorixafor becomes commercially available, or until the study is terminated by the Sponsor.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mavorixafor
Study Locations (20)
Other
- Medical University of Vienna - Medizinische Universität Wien - Vienna
- Aarhus University Hospital - Aarhus
- CHU Paris Est, Hôpital d'Enfants Armand-Trousseau - Paris
- Hopital Necker-Enfants Malades - Paris
- HaEmek Medical Center - Afula
- Emma Children's Hospital Academic Medical Center (AMC) - Amsterdam
- Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology - Moscow
- Academician I.P. Pavlov First Saint Petersburg State Medical University - Saint Pertersburg
- Seoul National University Hospital, Children's Hospital - Seoul
California
- University of California San Diego Health/Rady Children's Hospital - San Diego
- California Dermatology Institute - Thousand Oaks
Queensland
- Wesley Hospital - Auchenflower
- Children's Health Queensland Hospital - South Brisbane
Iowa
- University of Iowa - Iowa City
Maryland
- Johns Hopkins University Medical Center - Baltimore
Texas
- University of Texas Southwestern Medical Center - Dallas
Washington
- University of Washington Medical Center - Seattle
Rhne
- CHU de Lyon, Institut d'Hematologie et d'Oncologie Pediatrique - Lyon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-10-24 |
| Est. Completion | 2025-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03995108
The ClinicalTrials.gov registry entry for NCT03995108 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is X4 Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with WHIM Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03995108 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Queensland.
Frequently Asked Questions
What is clinical trial NCT03995108 about?
NCT03995108 is a clinical study titled "Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome". This study has a double-blind, Randomized Placebo-Controlled Period and an Open-Label Period. The primary objective of the Randomized Placebo-Controlled Period is to demonstrate the efficacy of mavorixafor in participants with WHIM syndrome as assessed by increasing levels of circulating neutrophils...
What is the current status of trial NCT03995108?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 2019-10-24. Estimated completion is 2025-12.
What conditions does trial NCT03995108 study?
This clinical trial studies the following conditions: WHIM Syndrome.
What interventions are being tested in trial NCT03995108?
The interventions under investigation include: Placebo (DRUG), Mavorixafor (DRUG).
Who is sponsoring clinical trial NCT03995108?
This trial is sponsored by X4 Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03995108 being conducted?
This trial has 20 study locations across California, Iowa, Maryland, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.